Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
20.02.2024 - Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology . Seite 1
Immunome, Inc. , a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. , a clinical-stage oncology company, that patient enrollment.
BOTHELL, Wash. (BUSINESS WIRE) Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in.